Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, September 2000, p. 759-763, Vol. 7, No. 5
Harvard School of Public Health, Boston,
Massachusetts1; University of Colorado
Health Sciences Center, Denver, Colorado2;
Johns Hopkins University School of Medicine, Baltimore,
Maryland3; Rush Medical College,
Chicago, Illinois4; University of
Texas Medical Branch, Galveston,5 and
Baylor College of Medicine, Houston,7
Texas; UCLA School of Medicine, Los
Angeles,6 and UCSF School of Medicine,
San Francisco,10 California;
University of North Carolina, Chapel Hill, North
Carolina8; and New York University
Medical Center, New York, New York9
Received 21 December 1999/Returned for modification 18 February
2000/Accepted 25 May 2000
Lymphocyte proliferation assays (LPAs) are widely used to assess
T-lymphocyte function of patients with human immunodeficiency virus
infection and other primary and secondary immunodeficiency disorders.
Since these assays require expertise not readily available at all
clinical sites, specimens may be shipped to central labs for testing.
We conducted a large multicenter study to evaluate the effects of
shipping on assay performance and found significant loss of LPA
activity. This may lead to erroneous results for individual subjects
and introduce bias into multicenter trials.
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Shipment Impairs Lymphocyte Proliferative Responses
to Microbial Antigens
*
Corresponding author. Mailing address: Division of
Pediatric Immunology, Johns Hopkins Hospital-CMSC 1102, 600 N. Wolfe
St., Baltimore, MD 21287-3923. Phone: (410) 955-5883. Fax: (410)
955-0229. E-mail: Hlederma{at}jhmi.edu.
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»